---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-225700"
form_type: "8-K"
ticker: "RVTY"
cik: "0000031791"
company_name: "REVVITY, INC."
filed_at: "2021-07-27T23:59:59+00:00"
generated_at: "2026-06-30T02:18:45.490657+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PerkinElmer to acquire BioLegend for $5.25B; expects $0.30 adjusted EPS accretion in first full year

## Summary
- Purchase price ~$5.25B; 59.5% cash and 40.5% stock at $156.3561/share.
- BioLegend estimated 2022 revenues ~$380M with mid-teens-plus growth.
- Expected $0.30 adjusted EPS accretion in 1st full year, >$0.50 in 2nd year.
- Revenue synergies expected $100M annually by 5th year post-close; no significant cost synergies planned.
- Bridge financing of $3.3B committed by Goldman Sachs; no financing condition.

## SEC filing metadata
- accession: 0001193125-21-225700
- form_type: 8-K
- ticker: RVTY
- cik: 0000031791
- company_name: REVVITY, INC.
- filed_at: 2021-07-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/31791/000119312521225700/0001193125-21-225700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/31791/000119312521225700/d205775d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-225700
- JSON: https://secwatch.observer/filing/0001193125-21-225700.json
- Plain text: https://secwatch.observer/filing/0001193125-21-225700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.